REG - Agronomics Limited - Agronomics invests A$3m in All G & Issue of Equity

AgronomicsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260115:nRSO9214Oa&default-theme=true

RNS Number : 9214O  Agronomics Limited  15 January 2026

15 January 2026

Agronomics Limited

("Agronomics (https://www.agronomics.im/) " or the "Company")

Agronomics invests AU$3 million in All G, Issue of Equity and TVR

Agronomics (LSE: ANIC) announces an additional investment of AU$3 million in
its portfolio company, All G Co Holdings Pty Limited ("All G"), an Australian
biotech specialising in precision fermentation of human and bovine milk
proteins, notably lactoferrin. This technology enables the production of
lactoferrin without the use of animals, supporting advancements in nutrition,
sustainability, and health.

All G's lactoferrin is cost-effective and environmentally sustainable,
suitable for applications in infant and clinical nutrition, functional foods,
skincare, and animal nutrition. The company has achieved significant
milestones and in November 2024, All G became the first company globally to
receive regulatory clearance for the sale of recombinant bovine lactoferrin in
China. In January 2025, the company achieved self-affirmed Generally
Recognised as Safe status for its animal free animal‑free bovine lactoferrin
in the US. In July, All G announced plans to launch lactoferrin in the US
and China during Q1 2026.

The new funding will support commercial-scale production, regulatory
submissions, patent development, and business expansion in Asia and Europe.

Note Purchase Agreement

Agronomics will invest the AU$ 3 million (c. £1,468,860) via a Note Purchase
Agreement ("NPA") as part of a minimum AU$10 million funding round, with notes
issued pursuant to a Convertible Note Instrument ("Instrument"). Notes issued
pursuant to the Instrument ("Notes") have a 24 month maturity period and are
issued with a coupon of 6% per annum. The Notes are convertible into new
shares of All-G subject to All-G completing a qualifying fundraise during the
term of the Notes. The conversion discount is 20% if a qualifying financing or
exit occurs within 18 months, or a 30% conversion discount if a qualifying
financing or exit occurs after 18 months. If no qualifying financing or exit
occurs within 24 months, the NPA is redeemable, unless 75% of the NPA holders
elect conversion.

 

The consideration due from Agronomics under the Note Purchase Agreement will
be satisfied in full by the issue of 10,026,375 new Ordinary Shares of the
Company, each new share issued at a price equal to 14.65 pence (being the net
asset value per share as at 30 September 2025).

 

Following this transaction, Agronomics' total investment in All G will be
approximately £8.9 million, representing about 4.99% of the Company's
reported NAV of £147.8 million.

TVR

Application has been made for the new shares to be admitted to trading on AIM,
with admission expected on 21 January 2026. Post-admission, the Company's
issued share capital will total 1,056,575,208 Ordinary Shares, all with voting
rights. The Company does not hold any Ordinary Shares in Treasury.
Shareholders should therefore use 1,056,575,208 as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) No. 596/2014, as it forms part of UK Domestic
Law by virtue of the European Union (Withdrawal) Act 2018. Upon the
publication of this announcement, this inside information is now considered to
be in the public domain.

About All G

All G is a Sydney-based biotechnology company that is at the forefront of
precision fermentation, developing high-value, human and bovine milk proteins
for use in functional foods, medical nutrition and infant nutrition. Learn
more at (https://www.allgfoods.com) www.allg.com (http://www.allg.com) .

About Agronomics

Agronomics is a leading London-listed company focused on investment
opportunities within the field of cellular agriculture. The Company has
established a portfolio of over 20 companies developing technologies that
produce food and materials historically derived from animals, offering
solutions for improved sustainability, human health, and food security.

A full list of Agronomics' portfolio companies is available at
www.agronomics.im (http://www.agronomics.im/) .

For further information, please contact:

 Agronomics Limited                               Beaumont              Cavendish Capital     Canaccord Genuity Limited  33Seconds

                                                  Cornish Limited       Markets                                          Limited

                                                                        Limited
 The Company                                      Nomad                 Joint Broker          Joint Broker               Public Relations
 Jim Mellon                                       Roland Cornish        Giles Balleny         Andrew Potts               Jack Ferris

 Denham Eke                                       James Biddle          Michael Johnson       Harry Pardoe               Amber Carr
 +44 (0) 1624 639396                              +44 (0) 207 628 3396  +44 (0) 207 397 8900  +44 (0) 207 523 8000       agronomics@33seconds.co (mailto:agronomics@33seconds.co)

 info@agronomics.im (mailto:info@agronomics.im)

 

Nominated Adviser Statement

Beaumont Cornish Limited ("Beaumont Cornish"), is the Company's Nominated
Adviser and is authorised and regulated in the United Kingdom by the Financial
Conduct Authority. Beaumont Cornish's responsibilities as the Company's
Nominated Adviser, including a responsibility to advise and guide the Company
on its responsibilities under the AIM Rules for Companies and AIM Rules for
Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont
Cornish is not acting for and will not be responsible to any other persons for
providing protections afforded to customers of Beaumont Cornish nor for
advising them in relation to the proposed arrangements described in the
announcement or any matter referred to in it.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPUQWGUPQGWC



            Copyright 2019 Regulatory News Service, all rights reserved